Global Thyroid Disorder Treatment Market Size By Drug Type (Levothyroxine, Liothyronine, Propylthiouracil), By Disease (Hypothyroidism, Hyperthyroidism), By Route Of Administration (Oral, Intravenous), By Geographic Scope And Forecast
갑상선 질환 치료 시장 규모와 예측
갑상선 질환 치료 시장 규모는 2024년에 22억 달러로 평가되었고 2026-2032년에 걸쳐 CAGR 3.17%를 나타내 2032년에는 28억 달러에 달할 것으로 예측되고 있습니다.
- 갑상선 질환 치료란, 레보티록신이나 항갑상선제 등의 약제를 이용해 갑상선 기능 저하증이나 갑상선 기능 항진증등의 상태를 컨트롤 하는 것입니다.이것의 치료는 갑상선 호르몬 레벨을 회복시켜, 증상을 경감하는 것을 목적으로 하고 있습니다
- 현재 갑상선 기능 항진증과 갑상선 기능 저하증의 치료에는 각각 방사성 요오드와 갑상선 호르몬 보충 요법이 사용되고 있습니다.
- 앞으로는 맞춤형 의료, 표적 치료, 유전자 편집의 진보가 치료의 중심이 될 가능성이 있습니다.새로운 의약품은 부작용을 최소한으로 억제하면서 치료 결과를 개선해, 보다 정확한 관리를 제공할 가능성이 있습니다.
세계의 갑상선 질환 치료 시장 역학
세계의 갑상선 질환 치료 시장을 형성하는 주요 시장 역학은 다음과 같습니다.
주요 시장 성장 촉진요인
- 발생률 증가 : 갑상선 기능 저하증이나 갑상선 기능 항진증 등 갑상선 질환의 발생이 증가하고 있으며, 발견률과 인지도의 향상도 도와 더 나은 치료법에 대한 요구가 높아지고있다
- 치료의 진보 : 제제의 개선이나 주문제작 등의 의약품 혁신에 의해 치료의 유효성과 매력이 향상해, 시장의 성장이 촉진됩니다.
- 인구의 고령화 : 갑상선 문제를 안기 쉬운 고령자 증가가 노화와 관련된 갑상선 질환에 적합한 대체 치료에 대한 수요를 높이고 있습니다.
- 헬스케어에의 액세스 : 신흥국에서의 헬스케어 인프라와 액세스의 향상에 의해 진단과 치료의 이용 가능성이 높아져, 지금까지 고민되지 않았던 영역에서 시장 성장이 촉진됩니다.
주요 이슈
- 인식 부족 : 갑상선 질환에 관한 지식이나 교육이 불충분하기 때문에 진단이나 치료가 늦어, 시장의 잠재력이 저하할 가능성이 있습니다.
- 접근 제한 : 농촌과 불우한 지역의 불충분 한 건강 관리 인프라가 진단과 치료를 방해하여 시장 성장을 제한 할 수 있습니다.
- 부작용과 문제 : 갑상선 질환에 의한 치료의 부작용과 문제는 환자의 컴플라이언스 위반으로 이어져 전체 시장의 수용성을 저하시킬 수 있습니다.
주요 동향
- 고도 진단 : 선진 진단 기기와 화상 진단 기술의 향상에 의해 갑상선 질환의 조기 한편 정확한 발견이 가능하게 되었습니다.
- 생물제제와 표적요법 : 갑상선질환의 근본적인 원인에 대처하기 위한 생물제제와 표적치료의 개발과 도입에 의해 새로운 치료법의 선택사항이 초래됩니다.
- 원격 의료 및 디지털 건강 : 원격 의료 및 디지털 건강 기술은 원격 모니터링 및 원격 관리에 점점 더 많이 사용되고 있으며, 환자의 치료에 대한 접근과 치료의 어드밴스를 향상시키고 있습니다.
목차
제1장 세계의 갑상선 질환 치료 시장 도입
제2장 주요 요약
제3장 VERIFIED MARKET RESEARCH의 조사 방법
- 데이터 마이닝
- 밸리데이션
- 1차 자료
- 데이터 소스 일람
제4장 세계의 갑상선 질환 치료 시장 전망
- 개요
- 시장 역학
- Porter's Five Forces 모델
- 밸류체인 분석
제5장 세계의 갑상선 질환 치료 시장 : 약제 유형별
- 개요
- 레보티록신
- 리오티로닌
- 프로필티오우라실
- 이미다졸계 화합물
- 베타 차단제
제6장 세계의 갑상선 질환 치료 시장 : 질환별
제7장 세계의 갑상선 질환 치료 시장 : 최종 사용자별
제8장 세계의 갑상선 질환 치료 시장 : 지역별
제9장 세계의 갑상선 질환 치료 시장 경쟁 구도
제10장 기업 프로파일
- AbbVie, Inc.
- Mylan NV
- Merck & Co., Inc.
- Pfizer, Inc.
- Abbott Laboratories
- Allergan plc
- Bayer AG
- Novartis AG
- Sanofi SA
- GlaxoSmithKline plc.
제11장 주요 개발
- 제품 출시/개발
- 합병과 인수
- 사업 확대
- 파트너십과 제휴
제12장 부록
KTH
Thyroid Disorder Treatment Market Size And Forecast
Thyroid Disorder Treatment Market size was valued at USD 2.2 Billion in 2024 and is projected to reach USD 2.8 Billion by 2032 growing at a CAGR of 3.17% from 2026 to 2032.
- Thyroid disorder treatment is controlling conditions such as hypothyroidism and hyperthyroidism using medications such as levothyroxine or antithyroid agents. These treatments are intended to restore thyroid hormone levels and reduce symptoms.
- Radioactive iodine and thyroid hormone replacement therapy are currently used to treat hyperthyroidism and hypothyroidism, respectively. Surgery may be considered in severe situations. Regular monitoring enables efficient management.
- In the future, treatments may center on customized medicine, targeted therapeutics and advances in gene editing. Emerging medicines may provide more precise management, improving outcomes while minimizing side effects.
Global Thyroid Disorder Treatment Market Dynamics
The key market dynamics that are shaping the global Thyroid Disorder Treatment Market include:
Key Market Drivers:
- Increasing Incidence: Rising occurrences of thyroid problems, including as hypothyroidism and hyperthyroidism, are driving need for better therapies, aided by increasing detection rates and awareness.
- Advancements in Treatment: Pharmaceutical innovations, such as improved medication formulations and tailored therapies, improve treatment efficacy and appeal, promoting market growth.
- Aging Population: The expanding older population, which is more prone to thyroid problems, adds to the demand for therapeutic alternatives suited to age-related thyroid conditions.
- Healthcare Access: Increasing healthcare infrastructure and access in emerging countries increases diagnostic and treatment availability, boosting market growth in previously neglected areas.
Key Challenges:
- Lack of Awareness: Inadequate knowledge and education about thyroid problems might result in delayed diagnosis and treatment, diminishing market potential.
- Limited Access: Inadequate healthcare infrastructure in rural or disadvantaged areas might impede diagnosis and treatment, limiting market growth.
- Adverse Effects and Problems: Treatment side effects and problems from thyroid disorders might lead to patient noncompliance and reduce overall market acceptance.
Key Trends:
- Advanced Diagnostics: Improvements in advanced diagnostic instruments and imaging techniques have resulted in earlier and more accurate detection of thyroid problems.
- Biologics and Targeted Therapies: The development and implementation of biologic medications and targeted therapies to address the underlying causes of thyroid problems, hence providing new therapeutic choices.
- Telemedicine and Digital Health: Telemedicine and digital health technologies are increasingly being used for remote monitoring and management, hence enhancing patient access to care and treatment adherence.
Global Thyroid Disorder Treatment Market Regional Analysis
Here is a more detailed regional analysis of the global Thyroid Disorder Treatment Market:
North America:
- According to Verified Market Research, North America is expected to dominate the global Thyroid Disorder Treatment Market.
- North America is likely to lead the worldwide thyroid disease treatment market due to its sophisticated healthcare infrastructure, high prevalence of thyroid disorders and major expenditure in R&D.
- The region's strong medical facilities and high levels of awareness help to maintain its leadership position, which is reinforced by ongoing advancements in treatment and diagnostics.
Asia Pacific:
- According to Verified Market Research, Asia Pacific is fastest growing region in global Thyroid Disorder Treatment Market.
- Asia-Pacific is the fastest-growing area in the worldwide thyroid disease treatment market, due to growing healthcare investments, rising thyroid condition prevalence and greater access to modern medical technologies. The region's high economic growth and improved healthcare facilities help to boost market expansion.
Global Thyroid Disorder Treatment Market: Segmentation Analysis
The Global Thyroid Disorder Treatment Market is segmented on the basis of Drug Type, Disease, Route of Administration, and Geography.
Thyroid Disorder Treatment Market, By Drug Type
- Levothyroxine
- Liothyronine
- Propylthiouracil
- Imidazole-based Compounds
- Beta-blockers
Based on Drug Type, The market is segmented into Levothyroxine, Liothyronine, Propylthiouracil, Imidazole-based Compounds, Beta-blockers. Levothyroxine is the most common drug type in the global thyroid disease treatment market, used to treat hypothyroidism and maintain normal thyroid hormone levels.
Thyroid Disorder Treatment Market, By Disease
- Hypothyroidism
- Hyperthyroidism
Based on Disease, The market is segmented into Hypothyroidism and Hyperthyroidism. Hypothyroidism dominates the worldwide thyroid problem treatment market due to its higher prevalence than hyperthyroidism. The requirement for lifelong hormone replacement therapy creates increasing market demand and treatment possibilities.
Thyroid Disorder Treatment Market, By End-User
Based on End-User, The market is segmented into Oral and Intravenous. The oral category leads the global thyroid disease therapy market due to its convenience, ease of administration and patient preference. Oral medicines are commonly used to treat thyroid problems.
Key Players
The "Global Thyroid Disorder Treatment Market" study report will provide valuable insight with an emphasis on the global market. The major players in the market are AbbVie, Inc., Mylan N.V., Merck & Co., Inc., Pfizer, Inc., Abbott Laboratories, Allergan plc, Bayer AG, Novartis AG, Sanofi S.A., GlaxoSmithKline plc.
Our market analysis also entails a section solely dedicated to such major players wherein our analysts provide an insight into the financial statements of all the major players, along with product benchmarking and SWOT analysis.
- Global Thyroid Disorder Treatment Market Recent Developments
- In December 2023, Aspen Global Incorporated, a subsidiary of Aspen Pharmacare Holdings Limited, reached an agreement with Sandoz AG to acquire its Chinese business. This strategic move was consistent with Aspen's strategy goal of increasing its footprint in China by using Sandoz's proven portfolio, infrastructure and experienced team for future growth in the region.
TABLE OF CONTENTS
1 INTRODUCTION OF GLOBAL THYROID DISORDER TREATMENT MARKET
- 1.1 Overview of the Market
- 1.2 Scope of Report
- 1.3 Assumptions
2 EXECUTIVE SUMMARY
3 RESEARCH METHODOLOGY OF VERIFIED MARKET RESEARCH
- 3.1 Data Mining
- 3.2 Validation
- 3.3 Primary Interviews
- 3.4 List of Data Sources
4 GLOBAL THYROID DISORDER TREATMENT MARKET OUTLOOK
- 4.1 Overview
- 4.2 Market Dynamics
- 4.2.1 Drivers
- 4.2.2 Restraints
- 4.2.3 Opportunities
- 4.3 Porters Five Force Model
- 4.4 Value Chain Analysis
5 GLOBAL THYROID DISORDER TREATMENT MARKET, BY DRUG TYPE
- 5.1 Overview
- 5.2 Levothyroxine
- 5.3 Liothyronine
- 5.4 Propylthiouracil
- 5.5 Imidazole-based Compounds
- 5.6 Beta-blockers
6 GLOBAL THYROID DISORDER TREATMENT MARKET, BY DISEASE
- 6.1 Overview
- 6.2 Hypothyroidism
- 6.3 Hyperthyroidism
7 GLOBAL THYROID DISORDER TREATMENT MARKET, BY END-USER
- 7.1 Overview
- 7.2 Oral
- 7.3 Intravenous
8 GLOBAL THYROID DISORDER TREATMENT MARKET, BY GEOGRAPHY
- 8.1 Overview
- 8.2 North America
- 8.2.1 U.S.
- 8.2.2 Canada
- 8.2.3 Mexico
- 8.3 Europe
- 8.3.1 Germany
- 8.3.2 U.K.
- 8.3.3 France
- 8.3.4 Rest of Europe
- 8.4 Asia Pacific
- 8.4.1 China
- 8.4.2 Japan
- 8.4.3 India
- 8.4.4 Rest of Asia Pacific
- 8.5 Rest of the World
- 8.5.1 Latin America
- 8.5.2 Middle East and Africa
9 GLOBAL THYROID DISORDER TREATMENT MARKET COMPETITIVE LANDSCAPE
- 9.1 Overview
- 9.2 Company Market Ranking
- 9.3 Key Development Strategies
10 COMPANY PROFILES
- 10.1 AbbVie, Inc.
- 10.1.1 Overview
- 10.1.2 Financial Performance
- 10.1.3 Product Outlook
- 10.1.4 Key Developments
- 10.2 Mylan N.V.
- 10.2.1 Overview
- 10.2.2 Financial Performance
- 10.2.3 Product Outlook
- 10.2.4 Key Developments
- 10.3 Merck & Co., Inc.
- 10.3.1 Overview
- 10.3.2 Financial Performance
- 10.3.3 Product Outlook
- 10.3.4 Key Developments
- 10.4 Pfizer, Inc.
- 10.4.1 Overview
- 10.4.2 Financial Performance
- 10.4.3 Product Outlook
- 10.4.4 Key Developments
- 10.5 Abbott Laboratories
- 10.5.1 Overview
- 10.5.2 Financial Performance
- 10.5.3 Product Outlook
- 10.5.4 Key Developments
- 10.6 Allergan plc
- 10.6.1 Overview
- 10.6.2 Financial Performance
- 10.6.3 Product Outlook
- 10.6.4 Key Developments
- 10.7 Bayer AG
- 10.7.1 Overview
- 10.7.2 Financial Performance
- 10.7.3 Product Outlook
- 10.7.4 Key Developments
- 10.8 Novartis AG
- 10.8.1 Overview
- 10.8.2 Financial Performance
- 10.8.3 Product Outlook
- 10.8.4 Key Developments
- 10.9 Sanofi S.A.
- 10.9.1 Overview
- 10.9.2 Financial Performance
- 10.9.3 Product Outlook
- 10.9.4 Key Developments
- 10.10 GlaxoSmithKline plc.
- 10.10.1 Overview
- 10.10.2 Financial Performance
- 10.10.3 Product Outlook
- 10.10.4 Key Developments
11 KEY DEVELOPMENTS
- 11.1 Product Launches/Developments
- 11.2 Mergers and Acquisitions
- 11.3 Business Expansions
- 11.4 Partnerships and Collaborations
12 Appendix
